Literature DB >> 2033387

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.

H Meyer1, G Sutter, A Mayr.   

Abstract

Different passages of the vaccinia virus strain Ankara (CVA wild-type) during attenuation to MVA (modified vaccinia virus Ankara) have been analysed to detect alterations in the genome. Physical maps for the restriction enzymes HindIII and XhoI have been established. Six major deletions relative to the wild-type strain CVA could be localized. They reduce the size of the entire genome from 208 kb (CVA wild-type) to 177 kb for the MVA strain. Four deletions occurred during the first 382 passages and the resulting variant (CVA 382) displays an attenuated phenotype similar to that of the MVA strain. The deletions are located in both terminal fragments, affect two-thirds of the host range gene K1L and eliminate 3.5 kb of a highly conserved region in the HindIII A fragment. During the next 190 passages leading to MVA two additional deletions appeared. Again, one is located in the left terminal fragment, and the other includes the A-type inclusion body gene. Neither of the deletions appear to participate in further attenuation of the virus. Rescue of the partially deleted host range region with the corresponding wild-type DNA restored the ability of the attenuated strains MVA and CVA 382 to grow in some non-permissive tissue cultures. Nevertheless, the complete host range of the wild-type strain was not recovered. Also, plaque-forming behaviour and reduced virulence were not influenced. From the data presented it may be concluded that the partially deleted host range gene is not solely responsible for attenuation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033387     DOI: 10.1099/0022-1317-72-5-1031

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  178 in total

1.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  Poxvirus-induced immunostimulating effects on porcine leukocytes.

Authors:  V Fachinger; T Schlapp; W Strube; N Schmeer; A Saalmüller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?

Authors:  Thorsten U Vogel; Thomas C Friedrich; David H O'Connor; William Rehrauer; Elizabeth J Dodds; Heather Hickman; William Hildebrand; John Sidney; Alessandro Sette; Austin Hughes; Helen Horton; Kathy Vielhuber; Richard Rudersdorf; Ivna P De Souza; Matthew R Reynolds; Todd M Allen; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

Authors:  Shahram Salek-Ardakani; Rachel Flynn; Ramon Arens; Hideo Yagita; Geoffrey L Smith; Jannie Borst; Stephen P Schoenberger; Michael Croft
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

5.  Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.

Authors:  Christine M Hughes; Frances K Newman; Whitni B Davidson; Victoria A Olson; Scott K Smith; Robert C Holman; Lihan Yan; Sharon E Frey; Robert B Belshe; Kevin L Karem; Inger K Damon
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

Review 6.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

7.  Replicon system for Lassa virus.

Authors:  Meike Hass; Uta Gölnitz; Stefanie Müller; Beate Becker-Ziaja; Stephan Günther
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

8.  Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

Authors:  Shawn S Jackson; Petr Ilyinskii; Valérie Philippon; Linda Gritz; Alicia Gómez Yafal; Kimberly Zinnack; Kristin R Beaudry; Kelledy H Manson; Michelle A Lifton; Marcelo J Kuroda; Norman L Letvin; Gail P Mazzara; Dennis L Panicali
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

9.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

10.  Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination.

Authors:  Garilyn M Jentarra; Michael C Heck; Jin Won Youn; Karen Kibler; Jeffrey O Langland; Carole R Baskin; Olga Ananieva; Yung Chang; Bertram L Jacobs
Journal:  Vaccine       Date:  2008-04-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.